| ID Source | ID |
|---|---|
| PubMed CID | 128739 |
| CHEMBL ID | 89126 |
| MeSH ID | M0142883 |
| Synonym |
|---|
| CHEMBL89126 |
| rb 7040 |
| 1-(2-nitroimidazol-1-yl)-3-(2,2,3,3-tetramethylaziridin-1-yl)propan-2-ol |
| 1h-imidazole-1-ethanol, 2-nitro-alpha-((2,2,3,3-tetramethyl-1-aziridinyl)methy)- |
| rb-7040 |
| 105027-76-7 |
| 1-(2-nitro-1h-imidazol-1-yl)-3-(2,2,3,3-tetramethylaziridin-1-yl)propan-2-ol |
| DTXSID40909306 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Maximum tolerated single, intraperitoneal doses (MTD) were determined in C3H/He mice bearing subcutaneous KHT sarcomas, and a drug dose-response relationship for radiosensitization was established for each compound administered at the optimum time (45-60 min) before local irradiation of tumors with a 10-Gy dose of X-rays." | ( Dual-function 2-nitroimidazoles as hypoxic cell radiosensitizers and bioreductive cytotoxins: in vivo evaluation in KHT murine sarcomas. Adams, GE; Cole, S; Fielden, EM; Jenkins, TC; Stratford, IJ, 1990) | 0.28 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID133777 | Maximum tolerated dose was determined for compound administered intraperitoneally as a suspension in arachis oil in C3H/He mice | 1990 | Journal of medicinal chemistry, Sep, Volume: 33, Issue:9 | Synthesis and evaluation of alpha-[[(2-haloethyl)amino]methyl]-2- nitro-1H-imidazole-1-ethanols as prodrugs of alpha-[(1-aziridinyl)methyl]-2- nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively activate |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 4 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.30) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||